<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Puricel, Serban</dc:creator>
  <dc:creator>Cuculi, Florim</dc:creator>
  <dc:creator>Weissner, Melissa</dc:creator>
  <dc:creator>Schmermun, Axel</dc:creator>
  <dc:creator>Jamshidi, Peiman</dc:creator>
  <dc:creator>Nyffenegger, Tobias</dc:creator>
  <dc:creator>Binder, Harald</dc:creator>
  <dc:creator>Eggebrecht, Holger</dc:creator>
  <dc:creator>Münzel, Thomas</dc:creator>
  <dc:creator>Cook, Stéphane</dc:creator>
  <dc:creator>Gori, Tommaso</dc:creator>
  <dc:date>2016-03-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Background Recent reports suggest an elevated incidence of bioresorbable vascular  scaffold (BVS) thrombosis (scaffold thrombosis [ScT]).Objectives This study  investigated occurrence rates, clinical and angiographic characteristics, and possible  mechanisms of ScT in all-comer patients undergoing BVS implantation at 2 German  and 2 Swiss hospitals.Methods A total of 1,305 consecutive patients (mean age 64  years, 78% male) who received 1,870 BVS (mean 1.4 ± 0.8 BVS/patient) were  enrolled. Clinical/procedural characteristics, mortality, and ScT data at 485 days  (range 312 to 652 days) were examined.Results ScT occurred in 42 patients. The  incidence of probable and definite ScT was 1.8% at 30 days and 3.0% at 12 months,  without differences among centers (p = 0.60). A total of 22 (52%) ScTs presented as  ST-segment elevation myocardial infarction and 6 (17%) as sudden cardiac death. In  multivariable analysis, ostial lesions (p = 0.049) and impaired left ventricular ejection  fraction (p = 0.019) were independently associated with ScT. Nine (21%) of the ScTs  occurred in patients who had suspended dual antiplatelet therapy, in 6 cases  prematurely. Lower post-procedural minimum lumen and reference vessel diameters  were hallmarks of ScT (all p &lt; 0.0001). The risk of ScT appeared to rapidly increase  for post-procedural minimum lumen diameters below 2.4 mm (for the 2.5- to 3.0-mm  BVS) and 2.8 mm (for the 3.5-mm BVS). When a BVS-specific implantation strategy  was implemented, 12-month ScT rates fell from 3.3% to 1.0%, an effect that remained  significant when adjusted for multivariable propensity score (p = 0.012; hazard ratio:  0.19; 95% confidence interval: 0.05 to 0.70).Conclusions The 12-month incidence of  ScT reached 3% and could be significantly reduced when an optimized implantation  strategy was employed. (retrospective multicentric registry and Mainz Intracoronary  Database. The Coronary Slow-flow and Microvascular Diseases Registry [MICAT];  NCT02180178)</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/304686</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/304686/files/coo_bcs.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/304686/files/coo_bcs_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jacc.2015.12.019</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of the American College of Cardiology. - 2016, vol. 67, no. 8, p. 921–931</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">bioresorbable scaffold</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">stent thrombosis</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/616</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
